Table 2.
Adjusted risk of switching/discontinuation by IL-inhibitor
| Drug (reference: risankizumab) | Discontinuation | Switching | ||||||
|---|---|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |||
| Brodalumab | 3.65 | 2.47 | 5.38 | < 0.0001 | 2.77 | 1.67 | 4.61 | < 0.0001 |
| Guselkumab | 2.70 | 1.90 | 3.86 | < 0.0001 | 2.45 | 1.54 | 3.91 | 0.0002 |
| Ixekizumab | 2.59 | 1.80 | 3.75 | < 0.0001 | 2.05 | 1.26 | 3.33 | 0.004 |
| Secukinumab | 3.69 | 2.61 | 5.23 | < 0.0001 | 2.67 | 1.68 | 4.24 | < 0.0001 |
| Ustekinumab | 2.07 | 1.42 | 3.01 | 0.0001 | 2.73 | 1.70 | 4.40 | < 0.0001 |
Values based on Cox multivariable regression model adjusting for demographics, comorbidities, and healthcare resource use
CI confidence interval, IL interleukin